Q&A

Reformulation Is Much Easier Than Developing A New Injectable Drug Product. So Why Aren't We Doing It More?

Evonik1

An interview with Dr. Tom Tice, Evonik Health Care

We all know about the significant financial costs and clinical risks involved in bringing a new injectable drug product to market.  So why isn’t reformulation or repurposing being used more often to meet these challenges?  In this interview with Dr. Tom Tice, one of the world’s leading experts on extended release injectables and implants, we review current and emerging areas of reformulation focus, and some best practices to get your strategy right.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online